Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
  • 264 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

  • 177 views
  • 08 Nov, 2020
  • 1 location
None
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, …

cyclosporine
panuveitis
tumor necrosis factor
antimetabolites
monoclonal antibodies
  • 112 views
  • 02 Aug, 2021
  • 33 locations
None
Safety of Splenic Stimulation for RA

Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). Five participants will be implanted with the device and receive neurostimulation for 12 weeks.

antirheumatics
DMARD
  • 0 views
  • 20 Aug, 2021
  • 1 location
None
Splenic Stimulation for RA

biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device

baricitinib
tumor necrosis factor
DMARD
  • 8 views
  • 03 Sep, 2021
  • 4 locations
None
The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis

rheumatic drugs are ineffective in the treatment of RA. The addition of tofacitinib to patients may be beneficial to the treatment.

stiffness
antirheumatics
synovitis
tofacitinib
DMARD
  • 0 views
  • 22 Jun, 2021
  • 1 location
None
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

, clinical trial with a two-fold clinical objective: To compare a standard step-up approach using conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs), such as methotrexate

  • 0 views
  • 24 Feb, 2021
  • 6 locations
None
Impact of Sacroiliac Joint Injection on Bone Marrow Edema

. The management of axial SpA is really challenging. The traditional disease-modifying anti-rheumatic drugs (DMARDs) were ineffective in controlling the axial disease. Biological agents such as tumor

  • 0 views
  • 30 May, 2021
  • 1 location
None
Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarker

Observation has pointed out, that osteitis present in the MRI scans, predicts bone erosion and that this in accordance with the concept by underlining the importance of bone marrow involvement in arthritis [Krabben A, 2013]. Abatacept with its favourable safety profile preferentially interrupts activation of nave T cells and perhaps …

  • 2 views
  • 24 Jan, 2021
None
TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study

This study compare the genomics profiles in synovial biopsies obtained prior to, and 24 weeks after a biologic disease modifying anti-rheumatic drugs (DMARDs)(Adalimumab, Ustekinumab, Guselkumab

vasectomy
NSAID
corticosteroids
methotrexate
biological drug
  • 1 views
  • 25 Mar, 2021
  • 2 locations